Manipulation of enzymatic activities of PAR-synthetizing and -degrading proteins, such as PARPs and PARG, has been explored in many pharmacological interventions of pathologies and shows much promise for future treatment of human diseases, including cancer, diabetes, and stroke, as well as inflammation. This evidence concerns the gene PARG and cancer.